BLASUBCUTANEOUS LYOPHILIZED POWERINJECTABLE1 Generic Approved
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
NUCALA (mepolizumab) by GSK is interleukin-5 antagonists [moa]. Approved for asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome and 1 more indications. First approved in 2015.
NUCALA (mepolizumab) is a monoclonal antibody that antagonizes interleukin-5 (IL-5), a key cytokine in eosinophil development and activation. It is administered as a subcutaneous injection and is indicated for the treatment of eosinophilic asthma and other eosinophil-mediated conditions. The drug works by reducing circulating and tissue eosinophils, thereby reducing inflammation and exacerbations in patients with elevated eosinophil counts. NUCALA represents a targeted biologic approach to severe asthma management and has established itself as a cornerstone therapy in the IL-5 antagonist class.
$0.3BPart D
Mechanism of Action
Interleukin-5 Antagonists
Pharmacologic Class:
Interleukin-5 Antagonist
Indications (4)
Worked on NUCALA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.